Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new oral drug combo, ML-007C-MA, significantly reduced schizophrenia symptoms in a mid-stage trial, hitting its primary endpoint with a twice-daily dose. The drug works via muscarinic receptors — not dopamine — offering a potentially tolerable alternative for patients who struggle with traditional antipsychotics. MapLight Therapeutics is now planning phase III discussions with the FDA.
A new schizophrenia contender enters the ring. ML-007C-MA, an investigational oral drug combining betovumeline and fesoterodine fumarate, significantly improved schizophrenia symptoms in adults experiencing acute psychosis, according to results from the phase II ZEPHYR trial presented at the NEI Fall Congress. The twice-daily 210/3 mg dose hit the primary endpoint — a statistically significant improvement in PANSS total score versus placebo at week 5 — and also met several key secondary endpoints, including cognitive performance gains.
What makes this drug stand out is its mechanism: rather than blocking dopamine receptors like most antipsychotics, it activates muscarinic M1/M4 receptors in the brain while simultaneously blocking peripheral cholinergic side effects (think nausea and GI distress). This dual-action design could be meaningful for patients who are intolerant of or don't respond to conventional treatments.
By the Numbers:
Why it matters: With only one other muscarinic agonist (Cobenfy) approved for schizophrenia — the first novel mechanism in over 30 years — ML-007C-MA could expand treatment options for a patient population with significant unmet needs. MapLight is now planning FDA discussions for phase III design.
